Willingdon Wealth Management raised its stake in Pfizer Inc. (NYSE:PFE) by 0.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 67,229 shares of the biopharmaceutical company’s stock after purchasing an additional 227 shares during the quarter. Willingdon Wealth Management’s holdings in Pfizer were worth $2,258,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in PFE. Altfest L J & Co. Inc. boosted its stake in shares of Pfizer by 67.0% in the second quarter. Altfest L J & Co. Inc. now owns 107,278 shares of the biopharmaceutical company’s stock valued at $3,603,000 after buying an additional 43,024 shares in the last quarter. HL Financial Services LLC raised its holdings in Pfizer by 1.1% during the second quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after purchasing an additional 35,744 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in Pfizer during the first quarter worth $13,342,000. Searle & CO. raised its holdings in Pfizer by 92.7% during the first quarter. Searle & CO. now owns 80,052 shares of the biopharmaceutical company’s stock worth $2,739,000 after purchasing an additional 38,500 shares during the last quarter. Finally, Hartford Financial Management Inc. raised its holdings in Pfizer by 10.8% during the second quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 835 shares during the last quarter. Institutional investors own 69.89% of the company’s stock.
In other news, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,280 shares of company stock valued at $2,118,988. 0.06% of the stock is owned by company insiders.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the previous year, the business earned $0.61 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. equities research analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.57%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.
Several equities analysts recently issued reports on the company. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. J P Morgan Chase & Co set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, October 31st. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. Pfizer presently has a consensus rating of “Buy” and an average price target of $38.66.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.